Description of impact
Case summarySince before the start of the national HPV vaccination programme (2008), the UK
Health Security Agency (UKHSA) has conducted surveillance and partnered in
research to inform and evaluate the use of HPV vaccines. This is part of the work
UKHSA undertakes to protect the nation’s health and reduce health inequalities.
Having established that the adolescent HPV vaccination programme was achieving
the expected impact in reducing HPV prevalence and HPV-related disease at the
population level, we have this year started to thoroughly explore its impact on
inequalities. So far, completed work includes collaboration with academic partners
on a systematic review of vaccination uptake (Dema et al, in press) and on a study of
cervical pre-cancer/cancer incidence (Falcaro et al, 2024), and analyses within
UKHSA of GUMCAD Surveillance data for genital warts diagnoses (Slater et al,
2024). Work is continuing to similarly analyse UKHSA’s HPV DNA surveillance data.
This project aims to inform approaches to HPV vaccination, including mop-up activity
(up to age 25 years), and the priorities and approaches for the NHS Cervical
Screening Programme as it addresses the remaining disease amongst vaccinationeligible women, supporting England’s aim to eliminate cervical cancer.
| Category of impact | Quality of life impacts, Health impacts |
|---|